Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice

Contrast Media and Molecular Imaging

Volumn 6, Issue 2, 2011, Pages 85-92

  Tchouate Gainkam, Lea Olive ^a   Caveliers, Vicky ^a,b   Devoogdt, Nick ^a   Vanhove, Christian ^a,b   Xavier, Catarina ^a   Boerman, Otto ^d   Muyldermans, Serge ^a,c   Bossuyt, Axel ^b   Lahoutte, Tony ^a,b  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gelofusine; Kidneys; Lysine; Megalin; Nanobody

Indexed keywords

7C12 TC 99M; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATIN SUCCINATE; LYSINE; MEGALIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG RETENTION; EX VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

ANIMALS; FEMALE; KIDNEY; LDL-RECEPTOR RELATED PROTEIN 2; LYSINE; MICE; MICE, INBRED C57BL; POLYGELINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-CHAIN ANTIBODIES; TECHNETIUM;

EID: 79954991349     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.408     Document Type: Article

References (39)

1. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136.
2. Adams GP, Tai MS, McCartney JE, et al. Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 2006; 12: 1599-1605.
3. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Meth 2001; 248: 47-66.
4. Sundaresan G, Yazaki PJ, Shively JE, et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003; 44: 1962-1969.
5. Tang Y, Wang J, Scollard DA, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 2005; 32: 51-58.
6. Burvenich IJ, Schoonooghe S, Blanckaert P, et al. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. Nucl Med Biol 2007; 34: 257-265.
7. Lauwereys M, Arbabi Ghahroudi M, Desmyter A, et al. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J 1998; 17: 3512-3520.
8. Vincke C, Loris R, Saerens D, et al. General strategy to humanize a camelid singledomain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 2009; 284: 3273-3284.
9. Saerens D, Pellis M, Loris R, et al. Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol 2005; 352: 597-607.
10. Gainkam LO, Huang L, Caveliers V, et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008; 49: 788-795.
11. Huang L, Gainkam LO, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imag Biol 2008; 10: 167-175.
12. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25: 201-212.
13. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55: 3825-3834.
14. Miao Y, Fisher DR, Quinn TP. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues. Nucl Med Biol 2006; 33: 723-733.
15. Akizawa H, Arano Y, Mifune M, et al. Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides. Nucl Med Biol 2001; 28: 761-768.
16. van Eerd JE, Vegt E, Wetzels JF, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006; 47: 528-533.
17. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47: 432-436.
18. Rolleman EJ, Bernard BF, Breeman WA, et al. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0, Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin 2008; 47: 110-115.
19. Roovers RC, Laeremans T, Huang L, et al. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56: 303-317.
20. Velikyan I, Sundberg AL, Lindhe O, et al. Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 2005; 46: 1881-1888.
21. Leheste JR, Rolinski B, Vorum H, et al. Megalin knockout mice as an animal model oflow molecular weight proteinuria. Am J Pathol 1999; 155: 1361-1370.
22. Leheste JR, Melsen F, Wellner M, et al. Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J 2003; 17: 247-249.
23. Vanhove C, Defrise M, Lahoutte T, Bossuyt A. Three-pinhole collimator to improve axial spatial resolution and sensitivity in pinhole SPECT. Eur J Nucl Med Mol Imag 2008; 35: 407-415.
24. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imag 2003; 2: 131-137.
25. Orlova A, Nilsson FY, Wikman M, et al. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 2006; 47: 512-519.
26. Ekblad T, Orlova A, Feldwisch J, et al. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorg Med Chem Lett 2009; 19: 3912-3914.
27. Birn H, Fyfe JC, Jacobsen C, et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 2000; 105: 1353-1361.
28. Verroust PJ, Christensen EI. Megalin and cubilin - the story of two multipurpose receptors unfolds. Nephrol Dial Transplant 2002; 17: 1867-1871.
29. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002; 3: 256-266.
30. de Jong M, Barone R, Krenning E, et al. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med 2005; 46: 1696-1700.
31. Vegt E, Eek A, Oyen WJ, et al. Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. Eur J Nucl Med Mol Imag 2010; 37(2): 226-234.
32. Vegt E, van Eerd JE, Eek A, et al. Reducing renal uptake of radiolabeled peptides using albumin fragments. J Nucl Med 2008; 49: 1506-1511.
33. Behr TM, Becker WS, Sharkey RM, et al. Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J Nucl Med 1996; 37: 829-833.
34. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imag 2003; 30: 9-15.
35. Gotthardt M, van Eerd-Vismale J, Oyen WJ, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007; 48: 596-601.
36. Wan L, Bellomo R, May CN. A comparison of 4% succinylated gelatin solution versus normal saline in stable normovolaemic sheep: global haemodynamic, regional blood flow and oxygen delivery effects. Anaesth Intensive Care 2007; 35: 924-931.
37. Stahl AR, Wagner B, Poethko T, et al. Renal accumulation of [111In]DOTATOC in rats: influence of inhibitors of the organic ion transport and diuretics. Eur J Nucl Med Mol Imag 2007; 34: 2129-2134.
38. Arano Y, Fujioka Y, Akizawa H, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999; 59: 128-134.
39. Fujioka Y, Arano Y, Ono M, et al. Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjug Chem 2001; 12: 178-185.